Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.84M | -26.25M | -30.84M | -37.30M | -40.34M |
| Total Depreciation and Amortization | 57.00K | 55.00K | 53.00K | 22.00K | 31.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.65M | 5.32M | 6.30M | 4.54M | 3.19M |
| Change in Net Operating Assets | 4.25M | 826.00K | 609.00K | 2.12M | 1.50M |
| Cash from Operations | -15.89M | -20.05M | -23.88M | -30.62M | -35.62M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 10.00M | 21.00M | 21.00M | 11.00M | 21.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.39M | 5.73M | 5.48M | 4.09M | 2.79M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.39M | 26.73M | 26.48M | 15.09M | 23.79M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -502.00K | 6.68M | 2.60M | -15.54M | -11.83M |